{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Cancer&page=6", "query": { "condition": "Clear Cell Renal Cell Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 327, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T05:16:01.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03849118", "title": "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-08-15", "completion_date": "2022-11-07", "has_results": true, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Glen Burnie", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849118" }, { "nct_id": "NCT01896271", "title": "High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Stereotactic Ablative Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2013-10-02", "completion_date": "2021-04-20", "has_results": true, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896271" }, { "nct_id": "NCT00002611", "title": "Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "0 Years to 15 Years" }, "enrollment_count": 3031, "start_date": "1995-07", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 206, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002611" }, { "nct_id": "NCT01472081", "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Clear-cell Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pazopanib", "type": "BIOLOGICAL" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2012-02-09", "completion_date": "2021-06-03", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 10, "location_summary": "Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01472081" }, { "nct_id": "NCT03035630", "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-cell Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Clear-cell Kidney Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guru Sonpavde", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-05-23", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035630" }, { "nct_id": "NCT05536141", "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Solid Tumors" ], "interventions": [ { "name": "casdatifan", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 362, "start_date": "2022-10-26", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05536141" }, { "nct_id": "NCT01243359", "title": "Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fluorine F 18 fluorothymidine", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243359" }, { "nct_id": "NCT00401128", "title": "Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 9, "start_date": "2004-05", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00401128" }, { "nct_id": "NCT00101972", "title": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "monoclonal antibody RAV12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2004-12", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 5, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101972" }, { "nct_id": "NCT02781506", "title": "Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "SAbR", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 7, "start_date": "2016-06-20", "completion_date": "2021-05-24", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-10-06T05:16:01.197Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02781506" } ] }